JUN 05, 2021 5:10 PM PDT

How is the new hospital price transparency rule going?

New findings from an analysis of hospital price transparency have been published recently in JAMA. The analysis was carried out by a team from Brigham and Women's Hospital and Massachusetts Eye and Ear following the introduction of a new requirement from The Centers for Medicare and Medicaid Services (CMS) that mandates that hospitals list their prices for services and items online. Despite this new requirement being a step in the right direction toward improving price transparency, the researchers’ analysis shows that it is not being regularly enforced.

"Reporting payer-negotiated prices is an important first step toward helping patients estimate the cost of care before receiving treatment," said corresponding author Roy Xiao, MD, MS, a resident in Otolaryngology-Head and Neck Surgery at the Brigham and Mass Eye and Ear. "Based on previous work, we expected to see some degree of variation, but the full range that we saw in our study was certainly surprising."

The study focused specifically on the price transparency and price variation for the treatment of thyroid cancer, which is known to be hugely expensive. Thyroid cancer patients boast the highest rates of bankruptcy among all cancer patients. The team’s analysis showed that only half of the cancer centers they looked at reported disclosing of payer-negotiated prices. Meanwhile, they also found a huge variation in prices between cancer care centers.

For example, between centers, they observed a 70-fold difference in the cost of radioactive iodine treatment and a 44-fold difference in the cost of neck computed tomography. They also saw a broad variation of prices even within the same center depending upon a patient’s health insurance.

Now, while this doesn’t necessarily shine a good light on hospitals and cancer care centers, the researchers say that it is important to take into account that they did their analysis soon after the introduction of the new requirement, meaning hospitals are still figuring out how to efficiently comply with the new rule. They have hope that disclosure rates and transparency will increase in the near future.

"Centers are facing a new reality when it comes to price transparency -- never before have they been required to make these rates available, and it's a huge lift to collect this information and make it available in a way that is intelligible to patients," said co-first author Vinay Rathi, MD, MBA, a resident in Otolaryngology-Head and Neck Surgery at the Brigham and Mass Eye and Ear. "As this information becomes available, we're interested in exploring how it can be used to help our patients."

Sources: JAMA, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
MAR 09, 2021
Cannabis Sciences
Cannabis Alleviates Neuropathic Pain from Chemotherapy
MAR 09, 2021
Cannabis Alleviates Neuropathic Pain from Chemotherapy
Neuropathic pain from oxaliplatin-based chemotherapy regimens occurs in up to 90% of patients, and continued exposure to ...
MAR 11, 2021
Cancer
Placenta structure resembles that of tumors
MAR 11, 2021
Placenta structure resembles that of tumors
Research published yesterday in the journal Nature provides further insight into how the placenta differs from other hum ...
MAR 19, 2021
Cancer
What does RNA editing do to the immune system?
MAR 19, 2021
What does RNA editing do to the immune system?
A recent study published in the journal Nature Communications from the University of Colorado Cancer Center explores new ...
MAY 18, 2021
Cancer
New guidelines change screening age for colorectal cancer to 45
MAY 18, 2021
New guidelines change screening age for colorectal cancer to 45
Following new guideline changes from the U.S. Preventive Services Task Force (USPSTF), individuals with an average risk ...
JUN 06, 2021
Cancer
New drug reduces tumor size in lung cancer patients with KRAS gene mutation
JUN 06, 2021
New drug reduces tumor size in lung cancer patients with KRAS gene mutation
The most recent results from the CODEBREAK 100 phase 2 clinical trial support the use of the drug sotorasib to reduce tu ...
JUN 11, 2021
Cell & Molecular Biology
Bad Fat in the Tumor Microenvironment May Disrupt Killer T Cells
JUN 11, 2021
Bad Fat in the Tumor Microenvironment May Disrupt Killer T Cells
The immune system can detect and destroy pathogenic and cancerous cells, but sometimes those dangerous cells can evade t ...
Loading Comments...